PURPOSE: An observational clinical and molecular study was designed to evaluate the effects of the administration of recombinant human FSH on sperm DNA fragmentation in men with a non-classical form of hypogonadotropic hypogonadism and idiopathic oligoasthenoteratozoospermia. METHODS: In the study were included 53 men with a non-classical form of hypogonadotropic hypogonadism and idiopathic oligoasthenoteratozoospermia. In all patients, sperm DNA fragmentation index (DFI), assessed by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate (dUTP) in situ DNA nick end-labelling (TUNEL) assay, was evaluated before starting the treatment with 150 IU of recombinant human FSH, given three times a week for at least 3 months. Patients' semen analysis and DNA fragmentation index were re-evaluated after the 3-month treatment period. RESULTS: After recombinant human FSH therapy, we did not find any differences in terms of sperm count, motility and morphology. The average DNA fragmentation index was significantly reduced (21.15 vs 15.2, p<0.05), but we found a significant reduction in patients with high basal DFI values (>15 %), while no significant variation occurred in the patients with DFI values ≤ 15 %. CONCLUSIONS: Recombinant human FSH administration improves sperm DNA integrity in hypogonadotropic hypogonadism and idiopathic oligoasthenoteratozoospermia men with DNA fragmentation index value >15 % .
PURPOSE: An observational clinical and molecular study was designed to evaluate the effects of the administration of recombinant human FSH on sperm DNA fragmentation in men with a non-classical form of hypogonadotropic hypogonadism and idiopathic oligoasthenoteratozoospermia. METHODS: In the study were included 53 men with a non-classical form of hypogonadotropic hypogonadism and idiopathic oligoasthenoteratozoospermia. In all patients, sperm DNA fragmentation index (DFI), assessed by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate (dUTP) in situ DNA nick end-labelling (TUNEL) assay, was evaluated before starting the treatment with 150 IU of recombinant human FSH, given three times a week for at least 3 months. Patients' semen analysis and DNA fragmentation index were re-evaluated after the 3-month treatment period. RESULTS: After recombinant human FSH therapy, we did not find any differences in terms of sperm count, motility and morphology. The average DNA fragmentation index was significantly reduced (21.15 vs 15.2, p<0.05), but we found a significant reduction in patients with high basal DFI values (>15 %), while no significant variation occurred in the patients with DFI values ≤ 15 %. CONCLUSIONS: Recombinant human FSH administration improves sperm DNA integrity in hypogonadotropic hypogonadism and idiopathic oligoasthenoteratozoospermiamen with DNA fragmentation index value >15 % .
Authors: D Sakkas; F Urner; P G Bianchi; D Bizzaro; I Wagner; N Jaquenoud; G Manicardi; A Campana Journal: Hum Reprod Date: 1996-04 Impact factor: 6.918
Authors: Saleela M Ruwanpura; Robert I McLachlan; Peter G Stanton; Kate L Loveland; Sarah J Meachem Journal: J Endocrinol Date: 2008-04 Impact factor: 4.286
Authors: Andrea Garolla; Marco Ghezzi; Ilaria Cosci; Barbara Sartini; Alberto Bottacin; Bruno Engl; Andrea Di Nisio; Carlo Foresta Journal: Endocrine Date: 2016-07-27 Impact factor: 3.633
Authors: A Barbonetti; A E Calogero; G Balercia; A Garolla; C Krausz; S La Vignera; F Lombardo; E A Jannini; M Maggi; A Lenzi; C Foresta; A Ferlin Journal: J Endocrinol Invest Date: 2018-02-01 Impact factor: 4.256
Authors: Rossella Cannarella; Sandro La Vignera; Rosita A Condorelli; Laura M Mongioì; Aldo E Calogero Journal: Asian J Androl Date: 2020 May-Jun Impact factor: 3.285